Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAALL-F01: Pegaspargase Dosing in Pediatric ALL
NCT02716233Phase 3Active, not recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2016
- Primary completion
- Apr 2022
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pegaspargase in acute lymphoblastic leukemia (ALL), sponsored by Assistance publique - Hôpitaux de Paris. Started Sep 2016; status: active, not recruiting.
02
Drugs
pegaspargase
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT02716233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02716233.